Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.
Abstract: Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (order Nidovirales) that causes respiratory and reproductive disease in equids. Protective, virus-neutralizing antibodies (VNAb) elicited by infection are directed predominantly against an immunodominant region in the membrane-proximal domain of the viral envelope glycoprotein G(L), allowing recently the establishment of a sensitive peptide enzyme-linked immunosorbent assay (ELISA) based on this particular domain (J. Nugent et al., J. Virol. Methods 90:167-183, 2000). By using an infectious cDNA we have now generated, in the controlled background of a nonvirulent virus, a mutant EAV from which this immunodominant domain was deleted. This virus, EAV-G(L)Delta, replicated to normal titers in culture cells, although at a slower rate than wild-type EAV, and caused an asymptomatic infection in ponies. The antibodies induced neutralized the mutant virus efficiently in vitro but reacted poorly to wild-type EAV strains. Nevertheless, when inoculated subsequently with virulent EAV, the immunized animals, in contrast to nonvaccinated controls, were fully protected against disease; replication of the challenge virus occurred briefly at low though detectable levels. The levels of protection achieved suggest that an immune effector mechanism other than VNAb plays an important role in protection against infection. As expected, infection with EAV-G(L)Delta did not induce a measurable response in our G(L)-peptide ELISA while the challenge infection of the animals clearly did. EAV-G(L)Delta or similar mutants are therefore attractive marker vaccine candidates, enabling serological discrimination between vaccinated and wild-type virus-infected animals.
Publication Date: 2003-07-15 PubMed ID: 12857916PubMed Central: PMC165223DOI: 10.1128/jvi.77.15.8470-8480.2003Google Scholar: Lookup The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The researchers have produced a live candidate marker vaccine for equine arteritis virus (EAV), by removing a crucial area of the virus that stimulates immune responses. However, the deletion doesn’t compromise the vaccine’s effectiveness, suggesting that another immune mechanism provides protection against infection. The modified virus could help differentiate between vaccinated and wild-type virus-infected animals.
Introduction to the Research
- The focus of the research lies in the development of a vaccine for the equine arteritis virus (EAV), a perpetrator of respiratory and reproductive diseases amongst horses. This virus belongs to the Arteriviridae family of viruses in the order of Nidovirales.
- Previously, a peptide enzyme-linked immunosorbent assay (ELISA) was developed, which effectively detected EAV presence owing to the virus-neutralizing antibodies targeting a dominant region of EAV – the G(L) domain.
Research Methodology
- The researchers utilized an infectious cDNA to create a mutant EAV that lacked the immunodominant G(L) domain. This manipulated virus expressed regular titers in cultured cells, but at a slower rate and caused no symptoms when introduced to ponies.
- The antibodies produced in response to this mutant virus effectively neutralized it in vitro but showed limited efficacy against wild-type strains of EAV.
- The researchers further exposed the vaccinated ponies to the more virulent strains of EAV and found these animals to be fully protected against disease, with only brief, low levels of viral replication noted. This protection level hints at the presence of an immune effector mechanism that provides protection against infection beyond the neutralization by antibodies.
Implications and Conclusion
- Interestingly, the infection with the mutant EAV (EAV-G(L)Delta) did not induce a measurable response in the G(L) peptide-based ELISA. However, the EAV infection did show a clear reaction in the same ELISA, enabling researchers to distinguish between vaccinated and wild-type virus-infected animals.
- Therefore, the researchers propose mutant viruses like EAV-G(L)Delta as promising marker vaccine candidates that facilitate distinguishing between vaccinated and infected animals – an essential feature for disease control and eradication strategies.
Cite This Article
APA
Castillo-Olivares J, Wieringa R, Bakonyi T, de Vries AA, Davis-Poynter NJ, Rottier PJ.
(2003).
Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.
J Virol, 77(15), 8470-8480.
https://doi.org/10.1128/jvi.77.15.8470-8480.2003 Publication
Researcher Affiliations
- Centre for Preventive Medicine, Animal Health Trust, Kentford, Newmarket, Suffolk CB8 7UU, United Kingdom.
MeSH Terms
- Animals
- Antibodies, Viral / blood
- Antibodies, Viral / immunology
- Arterivirus Infections / immunology
- Arterivirus Infections / prevention & control
- Arterivirus Infections / veterinary
- Arterivirus Infections / virology
- Cell Line
- Cells, Cultured
- Cricetinae
- Equartevirus / genetics
- Equartevirus / immunology
- Equartevirus / metabolism
- Equartevirus / pathogenicity
- Horse Diseases / immunology
- Horse Diseases / prevention & control
- Horse Diseases / virology
- Horses
- Immunization
- Lung / cytology
- Neutralization Tests
- Sequence Deletion
- Vaccines, Marker
- Viral Envelope Proteins / genetics
- Viral Vaccines / administration & dosage
- Viral Vaccines / genetics
- Viral Vaccines / immunology
References
This article includes 74 references
- Allen G, Yeargan M, Costa LR, Cross R. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1.. J Virol 1995 Jan;69(1):606-12.
- Babiuk LA, Lewis J, Suradhat S, Baca-Estrada M, Foldvari M, Babiuk S. Polynucleotide vaccines: potential for inducing immunity in animals.. J Biotechnol 1999 Aug 20;73(2-3):131-40.
- Babiuk LA. Broadening the approaches to developing more effective vaccines.. Vaccine 1999 Mar 26;17(13-14):1587-95.
- Babiuk LA, Babiuk SL, Baca-Estrada ME. Novel vaccine strategies.. Adv Virus Res 2002;58:29-80.
- Balasuriya UB, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF, Williams JC, Johnston RE, David Wilson W, Liu IK, James MacLachlan N. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses.. Vaccine 2002 Feb 22;20(11-12):1609-17.
- Balasuriya UB, Heidner HW, Hedges JF, Williams JC, Davis NL, Johnston RE, MacLachlan NJ. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles.. J Virol 2000 Nov;74(22):10623-30.
- Balasuriya UB, Maclachlan NJ, De Vries AA, Rossitto PV, Rottier PJ. Identification of a neutralization site in the major envelope glycoprotein (GL) of equine arteritis virus.. Virology 1995 Mar 10;207(2):518-27.
- Balasuriya UB, Patton JF, Rossitto PV, Timoney PJ, McCollum WH, MacLachlan NJ. Neutralization determinants of laboratory strains and field isolates of equine arteritis virus: identification of four neutralization sites in the amino-terminal ectodomain of the G(L) envelope glycoprotein.. Virology 1997 May 26;232(1):114-28.
- Balasuriya UB, Rossitto PV, DeMaula CD, MacLachlan NJ. A 29K envelope glycoprotein of equine arteritis virus expresses neutralization determinants recognized by murine monoclonal antibodies.. J Gen Virol 1993 Nov;74 ( Pt 11):2525-9.
- Balasuriya UB, Snijder EJ, van Dinten LC, Heidner HW, Wilson WD, Hedges JF, Hullinger PJ, MacLachlan NJ. Equine arteritis virus derived from an infectious cDNA clone is attenuated and genetically stable in infected stallions.. Virology 1999 Jul 20;260(1):201-8.
- Balasuriya UB, Timoney PJ, McCollum WH, MacLachlan NJ. Phylogenetic analysis of open reading frame 5 of field isolates of equine arteritis virus and identification of conserved and nonconserved regions in the GL envelope glycoprotein.. Virology 1995 Dec 20;214(2):690-7.
- BRYANS JT, CROWE ME, DOLL ER, MCCOLLUM WH. The blood picture and thermal reaction in experimental viral arteritis of horses.. Cornell Vet 1957 Jan;47(1):42-52.
- Bryans JT, Doll ER, Wilson JC, McCollum WH. Immunization for equine influenza.. J Am Vet Med Assoc 1966 Feb 15;148(4):413-7.
- Castillo-Olivares J, de Vries AAF, Raamsman MJB, Rottier PJM, Lakhani K, Westcott D, Tearle JP, Wood JLN, Mumford JA, Hannant D, Davis-Poynter NJ. Evaluation of a prototype sub-unit vaccine against equine arteritis virus comprising the entire ectodomain of the virus large envelope glycoprotein (G(L)): induction of virus-neutralizing antibody and assessment of protection in ponies.. J Gen Virol 2001 Oct;82(Pt 10):2425-2435.
- Chirnside ED, de Vries AA, Mumford JA, Rottier PJ. Equine arteritis virus-neutralizing antibody in the horse is induced by a determinant on the large envelope glycoprotein GL.. J Gen Virol 1995 Aug;76 ( Pt 8):1989-98.
- Collins, J. K., S. Kari, S. L. Ralston, D. G. Bennet, J. L. Traub Dargatz, and A. O. McKinnon. 1987. Equine viral arteritis in a veterinary teaching hospital. Prev. Vet. Med. 4:389-397.
- Dea S, Gagnon CA, Mardassi H, Pirzadeh B, Rogan D. Current knowledge on the structural proteins of porcine reproductive and respiratory syndrome (PRRS) virus: comparison of the North American and European isolates.. Arch Virol 2000;145(4):659-88.
- Deregt D, de Vries AA, Raamsman MJ, Elmgren LD, Rottier PJ. Monoclonal antibodies to equine arteritis virus proteins identify the GL protein as a target for virus neutralization.. J Gen Virol 1994 Sep;75 ( Pt 9):2439-44.
- de Vries, A. A. F. 1994. The molecular biology of equine arteritis virus. Ph.D. thesis. Utrecht University, Utrecht, The Netherlands.
- de Vries AA, Chirnside ED, Bredenbeek PJ, Gravestein LA, Horzinek MC, Spaan WJ. All subgenomic mRNAs of equine arteritis virus contain a common leader sequence.. Nucleic Acids Res 1990 Jun 11;18(11):3241-7.
- de Vries AA, Chirnside ED, Horzinek MC, Rottier PJ. Structural proteins of equine arteritis virus.. J Virol 1992 Nov;66(11):6294-303.
- de Vries AA, Glaser AL, Raamsman MJ, de Haan CA, Sarnataro S, Godeke GJ, Rottier PJ. Genetic manipulation of equine arteritis virus using full-length cDNA clones: separation of overlapping genes and expression of a foreign epitope.. Virology 2000 Apr 25;270(1):84-97.
- de Vries AA, Post SM, Raamsman MJ, Horzinek MC, Rottier PJ. The two major envelope proteins of equine arteritis virus associate into disulfide-linked heterodimers.. J Virol 1995 Aug;69(8):4668-74.
- Dobbe JC, van der Meer Y, Spaan WJ, Snijder EJ. Construction of chimeric arteriviruses reveals that the ectodomain of the major glycoprotein is not the main determinant of equine arteritis virus tropism in cell culture.. Virology 2001 Sep 30;288(2):283-94.
- BRYANS JT, CROWE ME, DOLL ER, MCCOLLUM WH. Isolation of a filterable agent causing arteritis of horses and abortion by mares; its differentiation from the equine abortion (influenza) virus.. Cornell Vet 1957 Jan;47(1):3-41.
- Doll ER, Bryans JT, Wilson JC, McCollum WH. Immunization against equine viral arteritis using modified live virus propagated in cell cultures of rabbit kidney.. Cornell Vet 1968 Oct;48(4):497-524.
- BRYANS JT, DOLL ER, KNAPPENBERGER RE. An outbreak of abortion caused by the equine arteritis virus.. Cornell Vet 1957 Jan;47(1):69-75.
- Edwards, S., J. Castillo-Olivares, A. Cullinane, J. Lable, J. Lenihan, J. A. Mumford, D. J. Paton, J. E. Pearson, R. Sinclair, D. G. F. Westcott, J. L. N. Wood, S. Zientara, and M. Nelly. 1998. International harmonization of laboratory diagnostic tests for equine viral arteritis, p. 359-362. In U. Wernery, J. F. Wade, J. A. Mumford, and O.-R. Kaaden (ed.), Proceedings of the 8th International Conference on Equine Infectious Diseases. R&W Publications, Newmarket, United Kingdom.
- Estes PC, Cheville NF. The ultrastructure of vascular lesions in equine viral arteritis.. Am J Pathol 1970 Feb;58(2):235-53.
- Fukunaga, Y., H. Imagawa, E. Tabuchi, and Y. Akiyama. 1981. Clinical and virological findings on experimental equine viral arteritis in horses. Bull. Equine Res. Inst. 18:110-118.
- Fukunaga Y, Matsumura T, Sugiura T, Wada R, Imagawa H, Kanemaru T, Kamada M. Use of the serum neutralisation test for equine viral arteritis with different virus strains.. Vet Rec 1994 May 28;134(22):574-6.
- Fukunaga Y, Wada R, Imagawa H, Kanemaru T. Venereal infection of mares by equine arteritis virus and use of killed vaccine against the infection.. J Comp Pathol 1997 Oct;117(3):201-8.
- Fukunaga, Y., R. Wada, T. Kanemaru, H. Imagawa, M. Kamada, and T. Samejima. 1996. Immune potency of lyophilized, killed vaccine for equine viral arteritis and its protection against abortion in pregnant mares. J. Equine Vet. Sci. 16:217-221.
- Fukunaga Y, Wada R, Matsumura T, Sugiura T, Imagawa H. Induction of immune response and protection from equine viral arteritis (EVA) by formalin inactivated-virus vaccine for EVA in horses.. Zentralbl Veterinarmed B 1990 Mar;37(2):135-41.
- Glaser AL, de Vries AA, Dubovi EJ. Comparison of equine arteritis virus isolates using neutralizing monoclonal antibodies and identification of sequence changes in GL associated with neutralization resistance.. J Gen Virol 1995 Sep;76 ( Pt 9):2223-33.
- Glaser AL, de Vries AA, Rottier PJ, Horzinek MC, Colenbrander B. Equine arteritis virus: a review of clinical features and management aspects.. Vet Q 1996 Sep;18(3):95-9.
- Hardy E, Santana H, Sosa A, Hernu00e1ndez L, Fernu00e1ndez-Patru00f3n C, Castellanos-Serra L. Recovery of biologically active proteins detected with imidazole-sodium dodecyl sulfate-zinc (reverse stain) on sodium dodecyl sulfate gels.. Anal Biochem 1996 Aug 15;240(1):150-2.
- Hyllseth B. Structural proteins of equine arteritis virus.. Arch Gesamte Virusforsch 1973;40(3):177-88.
- Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein.. J Mol Biol 1982 May 5;157(1):105-32.
- Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.. Nature 1970 Aug 15;227(5259):680-5.
- Magnusson P, Hyllseth B, Marusyk H. Morphological studies on equine arteritis virus.. Arch Gesamte Virusforsch 1970;30(2):105-12.
- McCollum WH. Development of a modified virus strain and vaccine for equine viral arteritis.. J Am Vet Med Assoc 1969 Jul 15;155(2):318-22.
- McCollum, W. H. 1970. Vaccination for equine arteritis virus, p. 143-151. In J. T. Bryans and H. Gerber (ed.), Proceeding of the 2nd International Conference on Equine Infectious Diseases. S. Karger, Basel, Switzerland.
- McCollum WH. Responses of horses vaccinated with avirulent modified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line to nasal inoculation with virulent virus.. Am J Vet Res 1986 Sep;47(9):1931-4.
- McCollum, W. H. 2002. Studies of passive immunity in foals to equine viral arteritis. Vet. Microbiol. 1:45-54.
- McCollum, W. H., and J. T. Bryans. 1973. Serological identification of infection by equine arteritis virus in horses of several countries, p. 256-263. In J. T. Bryans and H. Gerber (ed.), Proceedings of the 3rd International Conference on Equine Infectious Diseases. S. Karger, Basel, Switzerland.
- Mebatsion T, Koolen MJ, de Vaan LT, de Haas N, Braber M, Ru00f6mer-Oberdu00f6rfer A, van den Elzen P, van der Marel P. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope.. J Virol 2002 Oct;76(20):10138-46.
- Neu, S. M., P. J. Timoney, and S. R. Lowry. 1992. Changes in semen quality following experimental equine arteritis virus infection in the stallion. Theriogenology 37:407-431.
- Nugent J, Sinclair R, deVries AA, Eberhardt RY, Castillo-Olivares J, Davis Poynter N, Rottier PJ, Mumford JA. Development and evaluation of ELISA procedures to detect antibodies against the major envelope protein (G(L)) of equine arteritis virus.. J Virol Methods 2000 Nov;90(2):167-83.
- O'Neill T, Kydd JH, Allen GP, Wattrang E, Mumford JA, Hannant D. Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies.. Vet Immunol Immunopathol 1999 Sep 1;70(1-2):43-54.
- Peeters BP, de Leeuw OS, Verstegen I, Koch G, Gielkens AL. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.. Vaccine 2001 Feb 8;19(13-14):1616-27.
- Plagemann PG, Moennig V. Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses.. Adv Virus Res 1992;41:99-192.
- Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Snijder EJ, Meulenberg JJ. The molecular biology of arteriviruses.. J Gen Virol 1998 May;79 ( Pt 5):961-79.
- Snijder EJ, van Tol H, Pedersen KW, Raamsman MJ, de Vries AA. Identification of a novel structural protein of arteriviruses.. J Virol 1999 Aug;73(8):6335-45.
- Stadejek T, Bj Rklund H, Bascu Ana CR, Ciabatti IM, Scicluna MT, Amaddeo D, McCollum WH, Autorino GL, Timoney PJ, Paton DJ, Klingeborn B, Bel K S. Genetic diversity of equine arteritis virus.. J Gen Virol 1999 Mar;80 ( Pt 3):691-699.
- St-Laurent G, Lepage N, Carman S, Archambault D. Genetic and amino acid analysis of the GL protein of Canadian, American and European equine arteritis virus isolates.. Can J Vet Res 1997 Jan;61(1):72-6.
- Timoney PJ, McCollum WH. Equine viral arteritis.. Can Vet J 1987 Nov;28(11):693-5.
- Timoney, P. J., and W. H. McCollum. 1988. Equine viral arteritis: epidemiology and control. J. Equine Vet. Sci. 8:54-59.
- Timoney PJ, McCollum WH. Equine viral arteritis.. Vet Clin North Am Equine Pract 1993 Aug;9(2):295-309.
- Vaala WE, Hamir AN, Dubovi EJ, Timoney PJ, Ruiz B. Fatal, congenitally acquired infection with equine arteritis virus in a neonatal thoroughbred.. Equine Vet J 1992 Mar;24(2):155-8.
- van Berlo MF, Zeegers JJ, Horzinek MC, van der Zeijst BA. Antigenic comparison of equine arteritis virus (EAV) and lactic dehydrogenase virus (LDV); binding of staphylococcal protein A to the nucleocapsid protein of EAV.. Zentralbl Veterinarmed B 1983 May;30(4):297-304.
- van Dinten LC, den Boon JA, Wassenaar AL, Spaan WJ, Snijder EJ. An infectious arterivirus cDNA clone: identification of a replicase point mutation that abolishes discontinuous mRNA transcription.. Proc Natl Acad Sci U S A 1997 Feb 4;94(3):991-6.
- van Gennip HG, Bouma A, van Rijn PA, Widjojoatmodjo MN, Moormann RJ. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.. Vaccine 2002 Feb 22;20(11-12):1544-56.
- van Oirschot JT. Present and future of veterinary viral vaccinology: a review.. Vet Q 2001 Jul;23(3):100-8.
- van Oirschot JT, Kaashoek MJ, Rijsewijk FA, Stegeman JA. The use of marker vaccines in eradication of herpesviruses.. J Biotechnol 1996 Jan 26;44(1-3):75-81.
- Weiland E, Bolz S, Weiland F, Herbst W, Raamsman MJ, Rottier PJ, De Vries AA. Monoclonal antibodies directed against conserved epitopes on the nucleocapsid protein and the major envelope glycoprotein of equine arteritis virus.. J Clin Microbiol 2000 Jun;38(6):2065-75.
- Westcott, D., M. H. Lucas, and D. J. Paton. 1995. Equine arteritis virus: antigenic analysis of strain variation, p. 479-483. In M. Schwyzer, M. Ackermann, G. Bertoni, R. Kocherhaus, K. McCullough, M. Engels, R. Wittek, and R. Zanoni (ed.), Immunobiology of viral infections. Proceedings of the 3rd Congress of the European Society for Veterinary Virology. Fondation Marcel Merieux, Lyon, France.
- Widjojoatmodjo MN, van Gennip HG, Bouma A, van Rijn PA, Moormann RJ. Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines.. J Virol 2000 Apr;74(7):2973-80.
- Wieringa R, de Vries AA, Rottier PJ. Formation of disulfide-linked complexes between the three minor envelope glycoproteins (GP2b, GP3, and GP4) of equine arteritis virus.. J Virol 2003 Jun;77(11):6216-26.
- Wieringa R, de Vries AA, Raamsman MJ, Rottier PJ. Characterization of two new structural glycoproteins, GP(3) and GP(4), of equine arteritis virus.. J Virol 2002 Nov;76(21):10829-40.
- Wood JL, Chirnside ED, Mumford JA, Higgins AJ. First recorded outbreak of equine viral arteritis in the United Kingdom.. Vet Rec 1995 Apr 15;136(15):381-5.
- Yamaguchi, S., T. Kanno, H. Akashi, and T. Kondo. 1997. Identification of two neutralization sites in GL protein of equine arteritis virus by means of monoclonal antibodies. J. Equine Sci. 8:7-11.
- Zeegers JJ, Van der Zeijst BA, Horzinek MC. The structural proteins of equine arteritis virus.. Virology 1976 Aug;73(1):200-5.
Citations
This article has been cited 8 times.- Moyo NA, Westcott D, Simmonds R, Steinbach F. Equine Arteritis Virus in Monocytic Cells Suppresses Differentiation and Function of Dendritic Cells.. Viruses 2023 Jan 16;15(1).
- Balasuriya UB, Zhang J, Go YY, MacLachlan NJ. Experiences with infectious cDNA clones of equine arteritis virus: lessons learned and insights gained.. Virology 2014 Aug;462-463:388-403.
- Li P, Lu Z, Bai X, Li D, Sun P, Bao H, Fu Y, Cao Y, Chen Y, Xie B, Yin H, Liu Z. Evaluation of a 3A-truncated foot-and-mouth disease virus in pigs for its potential as a marker vaccine.. Vet Res 2014 May 1;45(1):51.
- Vu HL, Kwon B, de Lima M, Pattnaik AK, Osorio FA. Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus.. Vaccine 2013 Sep 13;31(40):4330-7.
- Balasuriya UB, Go YY, MacLachlan NJ. Equine arteritis virus.. Vet Microbiol 2013 Nov 29;167(1-2):93-122.
- Monastyrska I, Ulasli M, Rottier PJ, Guan JL, Reggiori F, de Haan CA. An autophagy-independent role for LC3 in equine arteritis virus replication.. Autophagy 2013 Feb 1;9(2):164-74.
- Fang Y, Snijder EJ. The PRRSV replicase: exploring the multifunctionality of an intriguing set of nonstructural proteins.. Virus Res 2010 Dec;154(1-2):61-76.
- Wieringa R, de Vries AA, van der Meulen J, Godeke GJ, Onderwater JJ, van Tol H, Koerten HK, Mommaas AM, Snijder EJ, Rottier PJ. Structural protein requirements in equine arteritis virus assembly.. J Virol 2004 Dec;78(23):13019-27.